Table 2.
MSC source, passage
|
Culture medium
|
Storage period and temperature
|
Cryopreservation
|
Viability
|
Phenotype
|
Results
|
Ref.
|
BM-MSC/P3 | MEM, 15% FBS, 1% P/S, 1% L-glutamin | 7 wk at -196 °C | 90% FBS and 10% DMSO | Osteogenic and adipogenic differentiation, high expression of CD44, CD73, CD90 and CD105 | No effects of freezing on function, differentiation and phenotype of the cells | [125] | |
1 x 106BM-MSC/P3, P4, P8, P13, P18 | MEM, 10% FBS, 1% P/S, 1% L-glutamin | 12 mo, controlled rate freezing at -80 °C | 30% FBS, 60% MEM and 10% DMSO | 85%-100% | Chondrogenic, adipogenic, neurogenic differentiation, no difference in expression of cell surface markers between passages | No differences in phenotype or differentiation between different cryopreserved MSCs from different passages | [82] |
0.5 x 106/mL; BM-MSC | MSC growth medium, 10% FBS | 1-5 mo, controlled rate freezing at -196 °C vs 4 d at 4 °C | Freezing medium (FM): 10% DMSO, 10% FBS, MSC growth medium, 30% BSA vs CryoStor (CS) animal component free freezing medium with 2%, 5% or 10% DMSO vs storage in HypoThermosol-FRS medium (HTS-FRS) at 4°C | FM 10% DMSO: 102.8%; CS 2% DMSO: 91.7%; CS 5% DMSO: 95.6%; CS 10% DMSO: 95.4%; HTS-FRS: 85.0% (rapid loss of viability after > 6 d) | Osteogenic differentiation, high expression of CD44, CD90, CD105, CD166, loss of expression of CD9 after hypothermic storage | No difference in differentiation or phenotype before and after freezing; HTS-FRS preserved MSC marker expression, proliferation and osteogenic differentiation after storage for at least 4 d | [81] |
1 x 106/mL; BM-MSC | MEM, 10% FBS, 1% P/S | 7 wk at -196 °C | 10% DMSO ± 10% or 90% FBS, 7.5% DMSO, 2.5% PEG ± 2% BSA, 5% DMSO, 5% PEG, 5% DMSO, 2% PEG, 3% Trehalose ± 2% BSA, 2.5% DMSO, 7.5% PEG ± 2% BSA, 10% Propanediol, 2%BSA, 7.5% Propanediol 2%BSA, 2.5% PEG | Highest viability with 7.5% DMSO, 2.5% PEG and 2% BSA: 82.9% ± 4.3% vs 10% DMSO: 82.7% ± 3.7% | Adipogenic, osteogenic and chondrogenic differentiation | In comparison to 10% DMSO, best results with 7.5% DMSO, 2.5% PEG and 2% BSA. In presence of and 2% BSA also good results with 5% DMSO, 5% PEG or 7.5% propanediol with 2.5% PEG | [84] |
BM-MSC/P1-6 | MEM, 10% Human Serum, 1% L-glutamine, 1% P/S | 1 yr at -196 °C | MEM, 40% Human Serum, 5% DMSO | Osteogenic, adipogenic and myogenic differentiation, before and after thawing high expression of CD73, CD90 and CD105, no expression of CD16, CD34, CD45 and HLA-DR | Cryopreserved MSCs show slightly lower proliferation rate, no differences in differentiation, senescence markers, CFU-F or karyotype between frozen and fresh cells | [89] | |
5 x 105/mL; BM-MSC/P1 | MEM, 15% FBS, 1% P/S | < 6 mo vs 33-37 mo | CELLBANKER cryopreservation medium (contains serum and DMSO) | 90% | Osteogenic differentiation, both fresh and cryopreserved MSCs were negative for CD14, CD34, CD45 and HLA-DR and positive for CD29 and CD105 | No difference in osteogenic potential between fresh and cryopreserved cells. Long-term cryopreserved MSCs retained high osteogenic potential, no difference in phenotype | [86] |
1 x 106/mL; WJ-MSC | ADMEM, 10% FBS, 1% P/S, 1% L-glutamine | 3 mo, controlled rate freezing at -196 °C | A: ADMEM, 10% PVP ± 10% FBS, B: ADMEM, 10% FBS, 0.05 mol/L glucose, 0.05 mol/L sucrose, 1.5 mol/L ethylene glycol ± 10% FBS, C: ADMEM, 10% DMSO ± 10% FBS | A: 62.9% ± 0.4%; A without FBS: 6.8% ± 0.2%; B: 72.2% ± 0.23%; C: 81.2% ± 0.6% | Adipogenic and osteogenic differentiation, both fresh and cryopreserved MSCs were negative for CD34 and CD45 and positive for CD73, CD90 and CD105 | Complete elimination of FBS in cryoprotectants resulted in drastic reduction in cell viability. Cryopreservation did not alter basic stem cell characteristics, plasticity and multipotency, except for proliferation rate | [83] |
1 x 106/mL; tgMSC | DMEM, 10% FBS, 1% P/S/A | 1 d or 6 mo, freezing at -196 °C | 20 μg/mL NaB, 20% FBS, 1% P/S/A , 10%, 7%, 5%, 3% or 0% DMSO | First cycle: > 90%; Second cycle: > 70%; Third cycle: > 80%; Fourth cycle: > 80% | Osteogenic, chondrogenic, and adipogenic differentiation, high expression of CD29 and CD73, medium expression of CD90, CD105 and CD166, no expression of CD14, CD45, CD34 | < 5% DMSO in freezing medium resulted in increased cell death, NaB improved cellular viability after freeze-thaw cycles, addition of NaB to the freezing medium did not affect differentiation capacity of MSCs | [85] |
5 x 105/mL ADSC/P2 | DMEM-LG, 10% FBS | 2 wk, freezing at -196 °C | 0.9% NaCl containing 10% DMSO HSA, HS, KSR or 90% FBS | DMSO + 9%; HSA: 78.0%; DMSO + 90%; HS: 72.4%; DMSO + 90%; KSR: 77.0%; DMSO + 90%; FBS: 78.5%; DMSO alone: 19.6% | No differences in adipogenic, osteogenic, and chondrogenic differentiation, gene expression of CD73, CD90, CD105, CD106, CD166, SCF, REX1 and NANOG. All ADSCs were positive for surface expression of CD44, CD73, CD90, CD105, CD166 and HLA-ABC and negative for CD31, CD34 and HLA-DR | ADSCs frozen with HSA, HS, or KSR showed similar growth kinetics as cells frozen with FBS. Multilineage differentiation of ADSCs did not differ between groups | [88] |
1 x 106/mL DPSC/P5-7 | MEM, 15% FBS, 1% P/S/A, 100 uM L- ascorbic acid 2-phosphate | 1 wk, freezing with Mr. Frosty (NMF) vs magnetic freezing (MF) | Serum-free cryopreservation medium (SFM) containing 3% DMSO, SFM + 10% DMSO, FBS + 3% DMSO, FBS + 10% DMSO | SFM + 3%; DMSO: 75%; SFM + 10%; DMSO: 78%; FBS + 3%; DMSO: 70%; FBS + 10%; DMSO: 73% | CD29, CD44 and STRO-1 expression did not differ between the NMF and the MF groups, whereas levels of CD73, CD90, CD146 and CD166 in the MF group increased compared to the NMF group. | DPSC viability using MF was significantly superior to that of the NMF using 2%–10% DMSO; Post-thaw MF-DPSCs expressed MSC markers and showed osteogenic and adipogenic differentiation similar to fresh DPSCs | [90] |
ESC-derived MSC | MEM, 10% FBS, 1% NEAA | Controlled rate freezing at 196 C | Sucrose, glycerol, creatine (SGC) and sucrose/ glycerol/isoleucine (SGI) solutions were incubated for 1h before freezing, Sucrose, mannitol, creatine (SMC) solutions were incubated for 2 h before freezing | SGI>SGC>SMC | Osteogenic and chondrogenic differentiation, all groups were positive for CD73, CD90 and CD105, and negative for CD45 | Osmolyte-based cryopreservation formulations retain MSC post-thaw viability, cell surface markers expression, proliferation, and osteochondral differentiation potential | [31] |
MSC: Mesenchymal stem/stromal cell; FBS: Fetal bovine serum; DMSO: Dimethyl sulfoxide; ESC: Embryonic stem cell; NEAA: Non essential aminoacids; MEM: minimal essential medium; KSR: Knockout serum replacement; BSA: Bovine serum albumin; P/S: Penicillin/Streptomycin; DPSC: Dental pulpa stem cells; ADSCs: Adipose derived stem cells.